Sign in
CompletedNo phase

UroCAD for Hematuria Evaluation--A Prospective, Multi-center Study

Key facts

Who runs it
Changhai Hospital
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
1,109 people enrolled
Started
8 Jun 2023
Ended
1 Jul 2025
Type of study
Observational, 2 groups
Treatments tested
  • urine sample collection
Record updated
12 November 2026

Who can take part

Age
18 years and older
Sex
Women and men

The registry criteria, word for word

Show all 7 criteriaShow less

Who can take part

  • Participants aged ≥ 18 years and signed informed consent form
  • Participants presented with hematuria (≥ 3 RBCs/HPF) and meet one of the following criteria:; Patients recommended to undergo cystoscopy or ureteroscopy; Patients with treatment-naïve, pathology-confirmed urothelial carcinoma; Patients diagnosed with benign genitourinary disease
  • Participants diagnosed with cancer other than urothelial carcinoma

Who cannot take part

  • Participants with history of urothelial carcinoma
  • Participants with urothelial carcinoma accompanied by other malignancy
  • Individuals unwilling to sign the consent form or unwilling to provide urine sample for test or quality of urine sample is poor
  • Patients unsuitable for this clinical trial

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Hematuria is recognized as an important sigh of potential urinary tract malignancy. Therefore, understanding the disease processes and discovering the potential urothelial carcinoma (UC) underlying this important sign is critical. Cystoscopy, urine cytology and imaging are most reliable methods for UC diagnosis, but certain drawbacks exist for these methods, such as invasiveness or inaccuracy. Chromosomal instability (CIN) is a hallmark of human cancer, and it's related with tumor stage and grade. Previous research has proved that analyzing CIN of the DNA extracted from urothelial cells in urine samples seems a promising method for detecting UC. Here the investigators intend to assess CIN's performance for hematuria evaluation.

The 2 groups in the trial

  • Hematuria patients

    Hematuria patients (≥ 3 RBCs/HPF) with treatment-naïve, pathology-confirmed urothelial carcinoma or benign genitourinary system disease or with undetermined lesion presented with hematuria.

    Treatment: urine sample collection

  • Non-hematuria patients

    Patients without hematuria and diagnosed with pathology-confirmed cancer other than urothelial cancer.

    Treatment: urine sample collection

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Hematuria Evaluation by Whole-genome Sequencing of Urine-Exfoliated Cell DNA, A Prospective, Multi-center Study
Record updated
12 November 2026